RhumbLine Advisers
MRSN

RhumbLine Advisers’s Mersana Therapeutics MRSN Stock Holding History

RhumbLine Advisers’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,167
Closed -$53K – 4216
2025
Q1 		$53K Sell
6,167
-707
-10% -$10.9K ﹤0.01% 3558
2024
Q4 		$246K Buy
6,874
+200
+3% +$10.3K ﹤0.01% 3097
2024
Q3 		$315K Sell
6,674
-369
-5% -$16.3K ﹤0.01% 2996
2024
Q2 		$354K Sell
7,043
-115
-2% -$8.31K ﹤0.01% 2905
2024
Q1 		$802K Buy
7,158
+755
+12% +$75.1K ﹤0.01% 2377
2023
Q4 		$371K Hold
6,403
– – ﹤0.01% 2836
2023
Q3 		$203K Sell
6,403
-192
-3% -$9.13K ﹤0.01% 3155
2023
Q2 		$542K Buy
6,595
+261
+4% +$38.2K ﹤0.01% 2638
2023
Q1 		$651K Buy
6,334
+215
+4% +$30.2K ﹤0.01% 2313
2022
Q4 		$896K Buy
6,119
+211
+4% +$35.7K ﹤0.01% 2191
2022
Q3 		$998K Buy
5,908
+486
+9% +$79K ﹤0.01% 2130
2022
Q2 		$626K Buy
5,422
+2,227
+70% +$209K ﹤0.01% 2370
2022
Q1 		$319K Sell
3,195
-36
-1% -$4.21K ﹤0.01% 2622
2021
Q4 		$502K Sell
3,231
-79
-2% -$15.4K ﹤0.01% 2507
2021
Q3 		$780K Buy
3,310
+97
+3% +$28.3K ﹤0.01% 2342
2021
Q2 		$1.09M Buy
3,213
+498
+18% +$189K ﹤0.01% 2210
2021
Q1 		$1.1M Sell
2,715
-87
-3% -$42.2K ﹤0.01% 2152
2020
Q4 		$1.86M Buy
2,802
+215
+8% +$120K ﹤0.01% 1881
2020
Q3 		$1.2M Sell
2,587
-179
-6% -$90.4K ﹤0.01% 1917
2020
Q2 		$1.62M Buy
2,766
+638
+30% +$218K ﹤0.01% 1847
2020
Q1 		$310K Buy
2,128
+274
+15% +$47.9K ﹤0.01% 2389
2019
Q4 		$266K Buy
1,854
+98
+6% +$7.17K ﹤0.01% 2648
2019
Q3 		$69K Buy
1,756
+177
+11% +$12.9K ﹤0.01% 2914
2019
Q2 		$160K Buy
1,579
+909
+136% +$107K ﹤0.01% 2844
2019
Q1 		$88K Buy
670
+26
+4% +$3.27K ﹤0.01% 2875
2018
Q4 		$66K Buy
644
+204
+46% +$32.3K ﹤0.01% 2921
2018
Q3 		$110K Sell
440
-31
-7% -$10.4K ﹤0.01% 2852
2018
Q2 		$211K Buy
+471
New +$207K ﹤0.01% 2707

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RhumbLine Advisers's MRSN Position: Q2 2025 in Review

RhumbLine Advisers sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 6,167 shares — an estimated $53K sold.

RhumbLine Advisers first reported a position in MRSN in Q2 2018 and held it in 28 quarters. The position peaked at $1.86M in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • RhumbLine Advisers reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 6,167 Mersana Therapeutics shares in Q2 2025, an estimated $53K.
  • RhumbLine Advisers first reported a position in Mersana Therapeutics in Q2 2018 and held it in 28 quarters.
  • RhumbLine Advisers's Mersana Therapeutics position peaked at $1.86M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.